September 2026 Catalyst Events
- 2026-09-01: Rhapsido (Remibrutinib) - (REMODEL-1) — Novartis AG — End of Phase Meeting
- 2026-09-01: envudeucitinib (ESK-001) - (LUMUS) — Alumis Inc. — Phase 2b
- 2026-09-01: Halneuron - (HALT-CINP / HAL-CINP-203) — Dogwood Therapeutics Inc. — Conference Presentation
- 2026-09-02: GTX-102 - (Aspire) — Ultragenyx Pharmaceutical Inc. — Phase 3
- 2026-09-02: RASONQUE (Daraxonrasib (RMC-6236)0 — Revolution Medicines Inc - Ordinary Shares — Phase 1/2
- 2026-09-02: Paxalisib — Kazia Therapeutics Limited — Preclinical
- 2026-09-02: Lanifibranor - (NATiV3) — Inventiva S.A. — Submission
- 2026-09-02: Ivonescimab (SMT112) with chemotherapy - (HARMONi-2) — Summit Therapeutics Inc. — Regulatory Decision
- 2026-09-02: Apitegromab - (FORGE) — Scholar Rock Holding Corporation — Phase 2
- 2026-09-02: GENGLYCOS (pariglasgene brecaparvovec-opnr) — Ultragenyx Pharmaceutical Inc. — Phase 3
- 2026-09-02: RASONQUE (Daraxonrasib (RMC-6236)) vs. Docetaxel - (RASolve-301) — Revolution Medicines Inc - Ordinary Shares — Phase 1/2
- 2026-09-02: BiPASS (Illuccix) — Teleflex Incorporated — Phase 3
- 2026-09-02: ACI-19764 — AC Immune SA — Initial Data
- 2026-09-02: TSC-101 - (ALLOHA-2) — TScan Therapeutics Inc. — Phase 3
- 2026-09-02: Namodenoson (CF102) — Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) — Interim Data
- 2026-09-02: TEV '408 — Teva Pharmaceutical Industries Limited American Depositary Shares — End of Phase Meeting
- 2026-09-02: TYVASO (treprostinil) - (TETON) — United Therapeutics Corporation — Regulatory Decision
- 2026-09-02: AMT-130 — uniQure N.V. — Submission
- 2026-09-03: Etentamig (ABBV-383) - (CERVINO) — AbbVie Inc. — End of Phase Meeting
- 2026-09-03: Bradykinin B2 receptor - (CHAPTER-1) — Pharvaris N.V. — Phase 2
- 2026-09-03: YUTREPIA (treprostinil) inhalation powder - (RE-WARM) — Liquidia Corporation — Phase 2a
- 2026-09-03: CLYM116 - (NAVIGATE-2) — Climb Bio Inc. — End of Phase Meeting
- 2026-09-03: Mipletamig in combination with venetoclax and azacitidine - (RAINIER) — Aptevo Therapeutics Inc. — Interim Data
- 2026-09-03: CLYM116 — Climb Bio Inc. — Initial Data
- 2026-09-04: ETCAMAH (Camizestrant) - (SERENA-6) — AstraZeneca PLC — Conference Presentation
- 2026-09-04: pelacarsen - (Lp(a)HORIZON) — Novartis AG — Conference Presentation
- 2026-09-04: ZANVASTRO (zilganersen) — Ionis Pharmaceuticals Inc. — Approved
- 2026-09-06: EPX-100 - (ARGUS) — Harmony Biosciences Holdings Inc. — Conference Presentation
- 2026-09-06: ARIKAYCE - (ENCORE) — Insmed Incorporated — Conference Presentation
- 2026-09-06: GRI-0621-IPF-02 — GRI Bio Inc. — Conference Presentation
- 2026-09-07: Azetukalner (XEN1101) - (X-TOLE2) — Xenon Pharmaceuticals Inc. — Conference Presentation
- 2026-09-08: INBRX-106 with Keytruda (pembrolizumab) — Inhibrx Biosciences Inc. — Initial Data
- 2026-09-08: DT120 ODT (Lysergide (LSD)) - (Emerge) — Definium Therapeutics Inc. — Phase 3
- 2026-09-08: GRI-0621-IPF-02 — GRI Bio Inc. — Phase 2a
- 2026-09-08: BGE-102 - (QUELL-DME) — BioAge Labs Inc. — Topline Data
- 2026-09-08: CMND-100 — Clearmind Medicine Inc. — Phase 1/2
- 2026-09-08: SZN-8141 — Surrozen Inc. — Submission
- 2026-09-08: SPY001, SPY002, SPY003 - (SKYLINE) — Spyre Therapeutics Inc. — Topline Data
- 2026-09-08: Tarlatamab (AMG 757) and durvalumab with durvalumab alone in first-line - (DeLLphi-305) — Amgen Inc. — Interim Data
- 2026-09-08: tozorakimab - (TITANIA) — AstraZeneca PLC — Regulatory Decision
- 2026-09-08: OST-HER2 (AOST-2121) — OS Therapies Incorporated — Submission
- 2026-09-08: Mavorixafor - (4WARD) — X4 Pharmaceuticals Inc. — End of Phase Meeting
- 2026-09-08: Deucrictibant (PHVS416) - (CHAPTER-3) — Pharvaris N.V. — Topline Data
- 2026-09-08: Mosliciguat - (PHocus) — Roivant Sciences Ltd. — Conference Presentation
- 2026-09-08: Telitacicept - (UPSTREAM MG) — Vor Biopharma Inc. — Topline Data
- 2026-09-08: tozorakimab - (OBERON) — AstraZeneca PLC — Regulatory Decision
- 2026-09-08: Aleniglipron (GSBR-1290) - (ACCESS and ACCESS II ) — Structure Therapeutics Inc. — Topline Data
- 2026-09-08: Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO) — Intellia Therapeutics Inc. — Regulatory Decision
- 2026-09-08: Delpacibart Etedesiran (del-desiran) - (HARBOR) — Novartis AG — End of Phase Meeting
- 2026-09-08: QRX003 — Quoin Pharmaceuticals Ltd. — Phase 2
- 2026-09-08: ACCG-2671 — Structure Therapeutics Inc. — Topline Data
- 2026-09-08: COYA 303 (COYA 301 + GLP-1RA) — Coya Therapeutics Inc. — Preclinical
- 2026-09-08: INBRX-106 with Keytruda (pembrolizumab) — Inhibrx Biosciences Inc. — Conference Presentation
- 2026-09-08: BEAM-302 — Beam Therapeutics Inc. — Conference Presentation
- 2026-09-08: BEAM-302 — Beam Therapeutics Inc. — Conference Presentation
- 2026-09-09: CT-202 — Context Therapeutics Inc. — Initial Data
- 2026-09-09: ORZEYFUL (Oveporexton (TAK-861-3001)) - (FirstLight) — Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) — Submission
- 2026-09-09: SER-252 (POZ-apomorphine) in combination with enFuse — Serina Therapeutics Inc. — Topline Data
- 2026-09-09: AX-0811 — ProQR Therapeutics N.V. — Initial Data
- 2026-09-09: OPGx-BEST1 - (BIRD-1) — Opus Genetics Inc. — Topline Data
- 2026-09-09: micvotabart pelidotin (PYX-201-101) - (MICVO) — Pyxis Oncology Inc. — End of Phase Meeting
- 2026-09-09: TYRA-300 - (SURF302) — Tyra Biosciences Inc. — Initial Data
- 2026-09-09: EVO756 — Evommune Inc. — Topline Data
- 2026-09-09: FT819 - (RECLAIM-LN) — Fate Therapeutics Inc. — Phase 1
- 2026-09-09: Obe-cel - (CARLYSLE) — Autolus Therapeutics plc — End of Phase Meeting
- 2026-09-09: DA-1726 — MetaVia Inc. — Topline Data
- 2026-09-09: BEAM-302 — Beam Therapeutics Inc. — Phase 1/2
- 2026-09-09: ersodetug (RZ358) - (sunRIZE) — Ligand Pharmaceuticals Incorporated — End of Phase Meeting
- 2026-09-09: COMP360 psilocybin - (COMP005) — COMPASS Pathways Plc — Submission
- 2026-09-09: OPGx-BEST1 - (BIRD-1) — Opus Genetics Inc. — Topline Data
- 2026-09-09: XP-8121 (levothyroxine sodium) — Xeris Biopharma Holdings Inc. — Conference Presentation
- 2026-09-10: DISC-3405 - (RESTORE-PV) — Disc Medicine Inc. — End of Phase Meeting
- 2026-09-10: PRT13722 — Prelude Therapeutics Incorporated — IND-Enabling
- 2026-09-10: HYRNUO (sevabertinib) - (SOHO-01) — Bayer AG ADR — Approved
- 2026-09-10: DISC-3405 - (RESTORE-PV) — Disc Medicine Inc. — Conference Presentation
- 2026-09-11: Leniolisib - (pediactric) — Pharming Group N.V. — Approved
- 2026-09-11: ISEMBYLD (apitegromab-mstn) - (SAPPHIRE) — Scholar Rock Holding Corporation — Approved
- 2026-09-11: MTX240 (OPB-171775) — Biodexa Pharmaceuticals plc — Submission
- 2026-09-11: Camizestrant - (SERENA-4) — AstraZeneca PLC — Phase 3
- 2026-09-11: α-lactalbumin — Anixa Biosciences Inc. — Conference Presentation
- 2026-09-11: TLX101-Px — Telix Pharmaceuticals Limited — Regulatory Decision
- 2026-09-11: TLX101-Px — Telix Pharmaceuticals Limited — Regulatory Decision
- 2026-09-14: KIMMTRAK with or without anti-PD1 therapy - (TEBE-AM) — Immunocore Holdings plc — Topline Data
- 2026-09-14: JNJ-5120/PIPE-307 - (MOONLIGHT-1) — Contineum Therapeutics Inc. — Phase 2
- 2026-09-14: SION-719 - (PreciSION CF) — Sionna Therapeutics Inc. — Phase 2a
- 2026-09-14: AP-SA02 - (diSARM) — Armata Pharmaceuticals Inc. — Phase 2a
- 2026-09-14: BRLIZIO (LPCN 1154) (oral brexanolone) - (BLOOM) — Lipocine Inc. — Phase 2
- 2026-09-14: Ameluz (aminolevulinic acid hydrochloride) topical gel in combination with the RhodoLED red-light lamp series — Biofrontera Inc. — Approved
- 2026-09-14: Pixclara (floretyrosine F 18 or 18F-FET) — Telix Pharmaceuticals Limited — Approved
- 2026-09-14: CRB-913 - (CANYON-1) — Corbus Pharmaceuticals Holdings Inc. — Topline Data
- 2026-09-14: DT120 ODT (MM120) lysergide tartrate - (Panorama) — Definium Therapeutics Inc. — Submission
- 2026-09-14: TBS-2025 - (VISTA) — TuHURA Biosciences Inc. — IND-Enabling
- 2026-09-14: JANX013 — Janux Therapeutics Inc. — Phase 1
- 2026-09-14: Zasocitinib (TAK-279) - (LATITUDE PsO) — Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) — Regulatory Decision
- 2026-09-14: CRB-913 - (CANYON-1) — Corbus Pharmaceuticals Holdings Inc. — Topline Data
- 2026-09-15: PH-762 — Phio Pharmaceuticals Corp. — End of Phase Meeting
- 2026-09-15: Rademikibart - (Seabreeze STAT Asthma) — Connect Biopharma Holdings Limited — Topline Data
- 2026-09-15: SERP-01 — Boundless Bio Inc. — Preclinical
- 2026-09-15: Bezisterim (NE3107) - (ADDRESS-LC) — BioVie Inc. — Topline Data
- 2026-09-15: Taletrectinib - (TRUST-I) (China) — Nuvation Bio Inc. Class A — Conference Presentation
- 2026-09-15: NS002 — Nasus Pharma Ltd. — Topline Data
- 2026-09-15: RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib) - (COPERNICUS) — Johnson & Johnson — Phase 2b
- 2026-09-15: COYA 302 - (ALSTARS) — Coya Therapeutics Inc. — Topline Data
- 2026-09-15: KETAFREE — NRX Pharmaceuticals Inc. — Regulatory Decision
- 2026-09-15: RP-A501 — Rocket Pharmaceuticals Inc. — Phase 2
- 2026-09-15: TRUTAKNA (atacicept-vymj) - (ORIGIN 3) — Vera Therapeutics Inc. — Conference Presentation
- 2026-09-15: AXPAXLI (OTX-TKI) - (SOL-1) — Ocular Therapeutix Inc. — Submission
- 2026-09-15: GTB-5550 TriKE (Sponsored (IST) protocol) — GT Biopharma Inc. — IND-Enabling
- 2026-09-15: Ebribafusp (AKB-097 (ADX-097)) — Akebia Therapeutics Inc. — Phase 2
- 2026-09-15: ERNA-201 — Ernexa Therapeutics Inc. — Submission
- 2026-09-15: Barzolvolimab (CDX-0159) - (EMBARQ-CSU1) — Celldex Therapeutics Inc. — Topline Data
- 2026-09-15: Tarcocimab tedromer (KSI-501) - (DAYBREAK) — Kodiak Sciences Inc — Topline Data
- 2026-09-15: Nanobody (sonelokimab) - (VELA-2) — MoonLake Immunotherapeutics — Submission
- 2026-09-15: Nanobody (sonelokimab) - (VELA-1) — MoonLake Immunotherapeutics — Submission
- 2026-09-15: AMT-130 - (Europe Trial) — uniQure N.V. — Topline Data
- 2026-09-15: Nanobody sonelokimab - (IZAR-1) — MoonLake Immunotherapeutics — Submission
- 2026-09-15: Remlifanserin (ACP-204) - (RADIANT) — ACADIA Pharmaceuticals Inc. — Topline Data
- 2026-09-15: Barzolvolimab (CDX-0159) - (EMBARQ-CSU2) — Celldex Therapeutics Inc. — Topline Data
- 2026-09-15: Laromestrocel (lomecel-B) - (ELPIS II) — Longeveron Inc. — Topline Data
- 2026-09-15: Seralutinib (GB002) - (TORREY/PROSERA) — Gossamer Bio Inc. — End of Phase Meeting
- 2026-09-15: Efzofitimod - (EFZO-FIT) — aTyr Pharma Inc. — End of Phase Meeting
- 2026-09-15: ABBV-706 — AbbVie Inc. — Conference Presentation
- 2026-09-15: ABBV-1480 (RC148) — AbbVie Inc. — Conference Presentation
- 2026-09-16: ONP-002 - (Australian trial) — Oragenics Inc. — Submission
- 2026-09-16: FT819 - (RECLAIM-LN) — Fate Therapeutics Inc. — Conference Presentation
- 2026-09-16: FT839-101 - (COMPLETE) — Fate Therapeutics Inc. — Conference Presentation
- 2026-09-16: Ateganosine (THIO-101) — MAIA Biotechnology Inc. — Phase 2
- 2026-09-17: azetukalner (XEN1101) - (X-NOVA) — Xenon Pharmaceuticals Inc. — Topline Data
- 2026-09-17: Alisertib - (PUMA-ALI-4201) in combination with paclitaxel - (ALISCA-Lung2) — Puma Biotechnology Inc — Phase 2
- 2026-09-17: Azetukalnerm - (X-ACKT) — Xenon Pharmaceuticals Inc. — Submission
- 2026-09-17: SGT-610 (patidegib) — Sol-Gel Technologies Ltd. — Phase 3
- 2026-09-17: MAR001 — Lisata Therapeutics Inc. — Conference Presentation
- 2026-09-17: MAR002 — Lisata Therapeutics Inc. — Topline Data
- 2026-09-17: FAYUVI (rebisufligene etisparvovec-hopf) — Ultragenyx Pharmaceutical Inc. — Approved
- 2026-09-17: Anaphylm (dibutepinephrine) - (103) — Aquestive Therapeutics Inc. — Submission
- 2026-09-17: Laromestrocel (lomecel-B) - (ELPIS II) — Longeveron Inc. — Topline Data
- 2026-09-17: Mim8 - (FRONTIER5) — Novo Nordisk A/S — Regulatory Decision
- 2026-09-17: IBTROZI (taletrectinib) — Nuvation Bio Inc. Class A — Regulatory Decision
- 2026-09-17: Ketamir-2 — MIRA Pharmaceuticals Inc. — Phase 2a
- 2026-09-17: Sotyktu (deucravacitinib) - (POETYK PsA-2) — Bristol-Myers Squibb Company — Conference Presentation
- 2026-09-17: OST-HER2 (AOST-2121) — OS Therapies Incorporated — Submission
- 2026-09-17: KERENDIA (finerenone) - (FINE-ONE) — Bayer AG ADR — Conference Presentation
- 2026-09-17: Fasedienol (PH94B) - (PALISADE-2) — Vistagen Therapeutics Inc. — Conference Presentation
- 2026-09-17: DT120 ODT (MM120) lysergide tartrate - (Panorama) — Definium Therapeutics Inc. — Topline Data
- 2026-09-18: Olanzapine LAI (44749) - (SOLARIS) — Teva Pharmaceutical Industries Limited — Regulatory Decision
- 2026-09-18: lanreotide injection, 120 mg/0.5 mL — Amneal Pharmaceuticals Inc. — Approved
- 2026-09-18: Inluriyo (imlunestrant) - (EMBER-3) — Eli Lilly and Company — Initial Data
- 2026-09-18: Efzimfotase alfa (ALXN1850) - (CHESTNUT) — AstraZeneca PLC — Phase 3
- 2026-09-18: XRx-026 — XORTX Therapeutics Inc. — Submission
- 2026-09-18: HMB-003 — Hemab Therapeutics Holdings Inc. — Phase 1
- 2026-09-18: OPGx-BEST1 - (BIRD-1) — Opus Genetics Inc. — Topline Data
- 2026-09-18: OPGx-BEST1 - (BIRD-1) — Opus Genetics Inc. — Topline Data
- 2026-09-18: Zidesamtinib (NVL-520) - (ARROS-1) — Nuvalent Inc. — Conference Presentation
- 2026-09-19: UX111 - (ABO-102) — Abeona Therapeutics Inc. — Regulatory Decision
- 2026-09-21: AP-SA02 - (diSARM) — Armata Pharmaceuticals Inc. — Phase 2
- 2026-09-21: OST-HER2 (AOST-2121) — OS Therapies Incorporated — Submission
- 2026-09-21: CUE-221 (UB-221) — Cue Biopharma Inc. — End of Phase Meeting
- 2026-09-21: ALKS 7290 — Alkermes plc — Topline Data
- 2026-09-21: Nu-3 gel — Lakewood-Amedex Biotherapeutics Inc. — End of Phase Meeting
- 2026-09-21: ARIKAYCE - (ENCORE) — Insmed Incorporated — Submission
- 2026-09-21: PRGN-2009 AdenoVerse — Precigen Inc. — Phase 1
- 2026-09-21: PRGN-2009 in combination with pembrolizumab — Precigen Inc. — Phase 2
- 2026-09-21: Foralumab - (INFORM-MS) — Tiziana Life Sciences Ltd — Phase 2a
- 2026-09-21: PRGN-2009 in combination with pembrolizumab — Precigen Inc. — Phase 2
- 2026-09-21: AP-SA02 - (diSARM) — Armata Pharmaceuticals Inc. — Conference Presentation
- 2026-09-21: WINREVAIR (sotatercept-csrk) - (HYPERION) — Merck & Company Inc. — Regulatory Decision
- 2026-09-21: WINREVAIR (sotatercept-csrk) - (HYPERION) — Merck & Company Inc. — Regulatory Decision
- 2026-09-22: paxalisib — Kazia Therapeutics Limited — Phase 1/2
- 2026-09-22: Crofelemer — Jaguar Health Inc. — Submission
- 2026-09-22: Tegoprubart (AT-1501) - (BESTOW) — Eledon Pharmaceuticals Inc. — End of Phase Meeting
- 2026-09-22: D-MAV Pan-filovirus program — Decoy Therapeutics Inc. — Preclinical
- 2026-09-22: Tovecimig (CTX-009 (DLL4 X VEGF-A bispecific)) - (COMPANION-002) — Compass Therapeutics Inc. — Submission
- 2026-09-22: PALI-2108 - (ASCENTRA-CD) — Palisade Bio Inc. — Phase 2
- 2026-09-22: PH94B - (PALISADE-4) — Vistagen Therapeutics Inc. — Phase 3
- 2026-09-22: Dazodalibep (HZN-4920) - (OASIZ 301) — Amgen Inc. — End of Phase Meeting
- 2026-09-22: Ateganosine (THIO-104) — MAIA Biotechnology Inc. — Interim Data
- 2026-09-22: NASARIX (PL-14) — Polyrizon Ltd. — Phase 1
- 2026-09-22: VK2735 (Maintainance Dosing) — Viking Therapeutics Inc. — Topline Data
- 2026-09-22: QRX003 — Quoin Pharmaceuticals Ltd. — Interim Data
- 2026-09-22: BRAVNETSA (Lutetium Lu 177 Dotatate) — Lantheus Holdings Inc. — Approved
- 2026-09-22: Simufilam — Filana Therapeutics Inc. — Phase 2a
- 2026-09-22: WINREVAIR (sotatercept-csrk) - (HYPERION) — Merck & Company Inc. — Approved
- 2026-09-22: Barzolvolimab (CDX-0159) - (EMBARQ-CSU1) — Celldex Therapeutics Inc. — Submission
- 2026-09-22: RAP-219 — Rapport Therapeutics Inc. — Conference Presentation
- 2026-09-22: Zilganersen (ION373) — Ionis Pharmaceuticals Inc. — Regulatory Decision
- 2026-09-23: IMVT-1402 (imeroprubart) — Roivant Sciences Ltd. — Topline Data
- 2026-09-23: NHBE GalNAc siRNA (WVE-007) - (INLIGHT) — Wave Life Sciences Inc. — Conference Presentation
- 2026-09-23: ACI-7104.056 - (VacSYn) — AC Immune SA — End of Phase Meeting
- 2026-09-23: Seralutinib (GB002) - (TORREY/PROSERA) — Gossamer Bio Inc. — Submission
- 2026-09-23: Everolimus — Amneal Pharmaceuticals Inc. — Approved
- 2026-09-23: ARCT-810 - (LUNAR-OTC) — Arcturus Therapeutics Holdings Inc. — End of Phase Meeting
- 2026-09-23: ARCT-810 - (LUNAR-OTC) — Arcturus Therapeutics Holdings Inc. — Conference Presentation
- 2026-09-23: IMNN-001 - (OVATION 3) — Imunon Inc. — Conference Presentation
- 2026-09-23: IMNN-001 - (OVATION 3) — Imunon Inc. — Conference Presentation
- 2026-09-23: DT120 ODT (MM120) lysergide tartrate - (Panorama) — Definium Therapeutics Inc. — Topline Data
- 2026-09-23: DURAVYU (EYP-1901) - (LUGANO) — EyePoint Inc. — Conference Presentation
- 2026-09-24: AVC-203 - (QUADvance) — Ligand Pharmaceuticals Incorporated — Phase 1a
- 2026-09-24: AVC-201 - (RevSTAR-123) — Ligand Pharmaceuticals Incorporated — Phase 1b
- 2026-09-24: NXP200 — Nuvectis Pharma Inc. — Submission
- 2026-09-24: Remigromig (MK-3000) - (BRUNELLO) — Merck & Company Inc. — Conference Presentation
- 2026-09-24: Miv-cel (mivocabtagene autoleucel, KYV-101) - (KYSA-6) — Kyverna Therapeutics Inc. — Conference Presentation
- 2026-09-24: PM647 — Prime Medicine Inc. — Initial Data
- 2026-09-24: forazapadin (SAT-3247) — Satellos Bioscience Inc. — IND-Enabling
- 2026-09-24: Efzofitimod - (EFZO-FIT) — aTyr Pharma Inc. — Submission
- 2026-09-24: Onswik (insulin efsitora alfa-gobe) — Eli Lilly and Company — Approved
- 2026-09-24: Remlifanserin (ACP-204) - (RADIANT) — ACADIA Pharmaceuticals Inc. — Conference Presentation
- 2026-09-24: IMNN-001 - (OVATION 2) — Imunon Inc. — Submission
- 2026-09-24: AXPAXLI (OTX-TKI) - (SOL-1) — Ocular Therapeutix Inc. — Conference Presentation
- 2026-09-24: DURAVYU (EYP-1901) - (LUGANO) — EyePoint Inc. — Conference Presentation
- 2026-09-24: AXPAXLI (OTX-TKI) - (SOL-1) — Ocular Therapeutix Inc. — Conference Presentation
- 2026-09-24: OCU410 - (ArMaDa) — Ocugen, Inc. — Conference Presentation
- 2026-09-25: Ifinatamab deruxtecan (DS-7300) - (IDeate-Lung01 ) — Merck & Company Inc. — Regulatory Decision
- 2026-09-25: Olumiant (baricitinib) - (BRAVE-AA-PEDS) — Incyte Corporation — Approved
- 2026-09-25: Atebrioz (zilurgisertib) - (PROGRESS) — Incyte Corporation — Approved
- 2026-09-25: CARVYKTI (ciltacabtagene autoleucel; cilta-cel) - (CARTITUDE-2) — Johnson & Johnson — End of Phase Meeting
- 2026-09-25: Imfinzi (durvalumab) - (VOLGA) — AstraZeneca PLC — Regulatory Decision
- 2026-09-25: Joenja (leniolisib) (children aged 4 years and older) — Pharming Group N.V. — Regulatory Decision
- 2026-09-25: Cemsidomide (CFT7455) in Combination With ELREXFIO (Elranatamab) — C4 Therapeutics Inc. — End of Phase Meeting
- 2026-09-25: RGX-314 - (ALTITUDE) — AbbVie Inc. — Conference Presentation
- 2026-09-25: ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) - (EXCALIBER-RRMM) — Bristol-Myers Squibb Company — Phase 3
- 2026-09-25: WELIREG (belzutifan) and LENVIMA (lenvatinib) - (LITESPARK-011) — Merck & Company Inc. — Interim Data
- 2026-09-25: Tambiciclib (SLS009) (GFH009) with venetoclax — SELLAS Life Sciences Group Inc. — Preclinical
- 2026-09-25: GLIX1 — BioLineRx Ltd. — Conference Presentation
- 2026-09-25: Cemsidomide (CFT7455) in combination with Dexamethasone - (MOMENTUM) — C4 Therapeutics Inc. — Conference Presentation
- 2026-09-25: Tambiciclib (SLS009) (GFH009) with venetoclax — SELLAS Life Sciences Group Inc. — Conference Presentation
- 2026-09-26: Zilurgisertib (INCB000928) - (PROGRESS) — Incyte Corporation — Regulatory Decision
- 2026-09-26: Zilurgisertib (INCB000928) - (PROGRESS) — Incyte Corporation — Regulatory Decision
- 2026-09-27: Relutrigine (PRAX-562) - (EMBOLD) — Praxis Precision Medicines Inc. — Regulatory Decision
- 2026-09-28: Nasal Foralumab - (Healey ALS) — Tiziana Life Sciences Ltd — Phase 2a
- 2026-09-28: JUVMO (tavapadon) - (TEMPO-2) — AbbVie Inc. — Approved
- 2026-09-28: MN-001 (Tipelukast) - (NATG-202) — MediciNova Inc. — Topline Data
- 2026-09-28: NTX-253 — Addex Therapeutics Ltd — Phase 1
- 2026-09-28: ALX148 + HERCEPTIN (Trastuzumab) + CYRAMZA (ramucirumab) and TAXOL (paclitaxel) - (ASPEN-06) — ALX Oncology Holdings Inc. — Topline Data
- 2026-09-28: LNTH-2401 (68Ga-DOTA-RM2) - (SPARROW) — Lantheus Holdings Inc. — Phase 2/3
- 2026-09-28: ARV-6723 — Arvinas Inc. — Initial Data
- 2026-09-28: Brelovitug - (AZURE) — Mirum Pharmaceuticals Inc. — Submission
- 2026-09-28: rinvatercept (KER-065) — Keros Therapeutics Inc. — Initial Data
- 2026-09-28: Pelareorep in combination with bevacizumab (Avastin) and leucovorin, fluorouracil, irinotecan (FOLFIRI) - (REO 033) — Oncolytics Biotech Inc. — Interim Data
- 2026-09-28: TTX-MC138 - (PRE-I-SPY) — TransCode Therapeutics Inc. — Phase 1a
- 2026-09-28: Zenkuda (Tarcocimab tedromer (KSI-501)) - (DAYBREAK) — Kodiak Sciences Inc — Topline Data
- 2026-09-28: SPR2015 — Merck & Company Inc. — Conference Presentation
- 2026-09-28: SIL204 — Silexion Therapeutics Corp — Phase 2/3
- 2026-09-28: Lynkuet (elinzanetant) - (OASIS-4) — Bayer AG ADR — Regulatory Decision
- 2026-09-28: Prulacabtagene leucel (prula-cel, formerly ADI-001) — Adicet Bio Inc. — Phase 1
- 2026-09-28: HMPL-A830 — GSK plc American Depositary Shares (Each representing two) — Phase 1
- 2026-09-28: 4D-150 - (4SIGHT) — 4D Molecular Therapeutics Inc. — Phase 2
- 2026-09-28: Tarcocimab tedromer (KSI-501) - (DAYBREAK) — Kodiak Sciences Inc — Topline Data
- 2026-09-28: Prulacabtagene leucel (prula-cel, formerly ADI-001) — Adicet Bio Inc. — Conference Presentation
- 2026-09-28: CMP-002 (CMP-SYNGAP-01) — CAMP4 Therapeutics Corporation — Initial Data
- 2026-09-28: Ameluz (aminolevulinic acid hydrochloride) topical gel in combination with the RhodoLED red-light lamp series — Biofrontera Inc. — Regulatory Decision
- 2026-09-29: Zeleciment basivarsen (z-basivarsen) (DYNE-101) - (ACHIEVE) — Dyne Therapeutics Inc. — Conference Presentation
- 2026-09-29: AL001-BD01 - (Lithium in Brain) — Alzamend Neuro Inc. — Conference Presentation
- 2026-09-29: Aglatimagene besadenovec (CAN-2409) - (ULYSSES) — Candel Therapeutics Inc. — Conference Presentation
- 2026-09-29: Aglatimagene besadenovec (CAN-2409) - (ULYSSES) — Candel Therapeutics Inc. — Conference Presentation
- 2026-09-30: SRP-4045 + SRP-4053 (ESSENCE) — Sarepta Therapeutics Inc. — Conference Presentation
- 2026-09-30: Ruxolitinib Cream - (TRuE-AD4) — Incyte Corporation — Conference Presentation
- 2026-09-30: Povorcitinib (INCB054707) - (STOP-HS) — Incyte Corporation — Conference Presentation
- 2026-09-30: Bempikibart - (SIGNAL-AA) — Q32 Bio Inc. — Conference Presentation
- 2026-09-30: Mim8 - (FRONTIER5) — Novo Nordisk A/S — Regulatory Decision
- 2026-09-30: Mounjaro (tirzepatide) - (SURPASS-CVOT) — Eli Lilly and Company — Conference Presentation
- 2026-09-30: Eloralintide and tirzepatide - (eloraTZP) — Eli Lilly and Company — Conference Presentation
- 2026-09-30: Retatrutide - (TRIUMPH) — Eli Lilly and Company — Conference Presentation
- 2026-09-30: forazapadin (SAT-3247 (CL-101)) - (BASECAMP) — Satellos Bioscience Inc. — Conference Presentation
- 2026-09-30: forazapadin (SAT-3247 (LT-001)) - (TRAILHEAD) — Satellos Bioscience Inc. — Conference Presentation
- 2026-09-30: OST-HER2 (AOST-2121) — OS Therapies Incorporated — Submission
- 2026-09-30: TYRA-300 - (SURF302) — Tyra Biosciences Inc. — Initial Data
- 2026-09-30: Bezisterim (NE3107) - (ADDRESS-LC) — BioVie Inc. — Topline Data
- 2026-09-30: Apitegromab - (SAPPHIRE) — Scholar Rock Holding Corporation — Regulatory Decision
- 2026-09-30: ORKA-001 - (EVERLAST-A) — Oruka Therapeutics Inc. — Interim Data
- 2026-09-30: SCY-770 (PXL-770) — SCYNEXIS Inc. — Topline Data
- 2026-09-30: CNM-Au8 - (HEALEY ALS) — Clene Inc. — Submission
- 2026-09-30: SCY-247 — SCYNEXIS Inc. — Topline Data
- 2026-09-30: Low-dose infigratinib - (PROPEL3) — BridgeBio Pharma Inc. — Submission
- 2026-09-30: OST-HER2 (AOST-2121) — OS Therapies Incorporated — Submission
- 2026-09-30: Anaphylm (dibutepinephrine) - (103) — Aquestive Therapeutics Inc. — Submission
- 2026-09-30: Laromestrocel (lomecel-B) - (ELPIS II) — Longeveron Inc. — Topline Data
- 2026-09-30: Rademikibart - (Seabreeze STAT Asthma) — Connect Biopharma Holdings Limited — Topline Data
- 2026-09-30: GR-MD-02 (belapectin) - (NAVIGATE) — Galectin Therapeutics Inc. — Submission
- 2026-09-30: ESK-001 - (LUMUS) — Alumis Inc. — Topline Data
- 2026-09-30: Tarcocimab tedromer (KSI-501) - (DAYBREAK) — Kodiak Sciences Inc — Topline Data
- 2026-09-30: Seralutinib (GB002) - (TORREY/PROSERA) — Gossamer Bio Inc. — End of Phase Meeting
- 2026-09-30: VYD2311 - (LIBERTY) — Invivyd Inc. — Topline Data
- 2026-09-30: VYD2311 - (DECLARATION) — Invivyd Inc. — Topline Data
- 2026-09-30: BDC-4182 — Bolt Biotherapeutics Inc. — Initial Data
- 2026-09-30: Miv-cel (mivocabtagene autoleucel, KYV-101) - (KYSA-6) — Kyverna Therapeutics Inc. — Topline Data
- 2026-09-30: OST-HER2 (AOST-2121) — OS Therapies Incorporated — Submission
- 2026-09-30: ADI-212 — Adicet Bio Inc. — Submission
- 2026-09-30: Halneuron - (HALT-CINP / HAL-CINP-203) — Dogwood Therapeutics Inc. — Topline Data
- 2026-09-30: DT120 ODT (MM120) lysergide tartrate - (Panorama) — Definium Therapeutics Inc. — Topline Data
- 2026-09-30: Miv-cel (mivocabtagene autoleucel, KYV-101) - (KYSA-8) — Kyverna Therapeutics Inc. — Topline Data
- 2026-09-30: Barzolvolimab (CDX-0159) - (EMBARQ-CSU1) — Celldex Therapeutics Inc. — Topline Data
- 2026-09-30: ACCG-2671 — Structure Therapeutics Inc. — Initial Data
- 2026-09-30: Aleniglipron (GSBR-1290) - (ACCESS and ACCESS II ) — Structure Therapeutics Inc. — Topline Data
- 2026-09-30: Barzolvolimab (CDX-0159) - (EMBARQ-CSU2) — Celldex Therapeutics Inc. — Topline Data
- 2026-09-30: ERNA-101 — Ernexa Therapeutics Inc. — Submission
- 2026-09-30: Nanobody sonelokimab - (IZAR-1) — MoonLake Immunotherapeutics — Submission
- 2026-09-30: TX2100 — Tectonic Therapeutic Inc. — Topline Data
- 2026-09-30: EVO756 — Evommune Inc. — Initial Data
- 2026-09-30: Apitegromab - (SAPPHIRE) — Scholar Rock Holding Corporation — Regulatory Decision
- 2026-09-30: DT120 ODT (MM120) lysergide tartrate - (Panorama) — Definium Therapeutics Inc. — Topline Data
- 2026-09-30: CLN-978 - (OUTRACE RA) — Cullinan Therapeutics Inc. — Initial Data
- 2026-09-30: Brelovitug - (AZURE) — Mirum Pharmaceuticals Inc. — Topline Data
- 2026-09-30: CTX-009 - (COMPANION-003) — Compass Therapeutics Inc. — End of Phase Meeting
- 2026-09-30: CRB-913 - (CANYON-1) — Corbus Pharmaceuticals Holdings Inc. — Topline Data
- 2026-09-30: Avexitide (Exendin 9-39) - (LUCIDITY) — Amylyx Pharmaceuticals Inc. — Initial Data
- 2026-09-30: Prulacabtagene leucel (prula-cel, formerly ADI-001) — Adicet Bio Inc. — Interim Data
- 2026-09-30: BMF-650 (GLP-131) — Biomea Fusion Inc. — Initial Data
- 2026-09-30: UGN-103 - (UTOPIA) — UroGen Pharma Ltd. — Submission
- 2026-09-30: CRB-913 - (CANYON-1) — Corbus Pharmaceuticals Holdings Inc. — Topline Data
- 2026-09-30: VK2735 - (VANQUISH-2) — Viking Therapeutics Inc. — Interim Data
- 2026-09-30: VK2735 (Oral) - (VENTURE) — Viking Therapeutics Inc. — Interim Data
- 2026-09-30: AMT-130 — uniQure N.V. — Topline Data
- 2026-09-30: VK2735 (Maintainance Dosing) — Viking Therapeutics Inc. — Initial Data
- 2026-09-30: DISC-3405 - (RESTORE-PV) — Disc Medicine Inc. — Initial Data
- 2026-09-30: AMT-130 - (Europe Trial) — uniQure N.V. — Topline Data
- 2026-09-30: Seralutinib (GB002) - (TORREY/PROSERA) — Gossamer Bio Inc. — End of Phase Meeting
- 2026-09-30: Efgartigimod - (ALKIVIA) — argenx SE — Topline Data
- 2026-09-30: Halneuron - (HALT-CINP / HAL-CINP-203) — Dogwood Therapeutics Inc. — Topline Data
- 2026-09-30: Apitegromab - (SAPPHIRE) — Scholar Rock Holding Corporation — Regulatory Decision
- 2026-09-30: Remlifanserin (ACP-204) - (RADIANT) — ACADIA Pharmaceuticals Inc. — Topline Data
- 2026-09-30: Viaskin Peanut - (VITESSE) — DBV Technologies S.A. — Submission
- 2026-09-30: ERNA-101 — Ernexa Therapeutics Inc. — Submission
- 2026-09-30: ERNA-101 — Ernexa Therapeutics Inc. — Submission
- 2026-09-30: Eftilagimod alpha (efti) - (TACTI-004/KEYNOTE-F91) — Immutep Limited — Full Results
- 2026-09-30: MN-001 (Tipelukast) - (NATG-202) — MediciNova Inc. — Topline Data
- 2026-09-30: SCY-770 (PXL-770) — SCYNEXIS Inc. — Topline Data
- 2026-09-30: VOXZOGO - (ASPEN) — BioMarin Pharmaceutical Inc. — Submission
- 2026-09-30: BMF-650 (GLP-131) — Biomea Fusion Inc. — Initial Data
- 2026-09-30: Low-dose infigratinib - (PROPEL3) — BridgeBio Pharma Inc. — Submission
- 2026-09-30: Viaskin Peanut - (VITESSE) — DBV Technologies S.A. — Submission
- 2026-09-30: Revita - (REMAIN-1) — Fractyl Health, Inc. — Interim Data
- 2026-09-30: GR-MD-02 (belapectin) - (NAVIGATE) — Galectin Therapeutics Inc. — Submission
- 2026-09-30: VK2735 — Viking Therapeutics Inc. — Initial Data
- 2026-09-30: CT-95 (mesothelin) — Context Therapeutics Inc. — Initial Data
- 2026-09-30: RGX-202 - (AFFINITY DUCHENNE) — REGENXBIO Inc. — Submission
- 2026-09-30: Nanobody (sonelokimab) - (VELA-1) — MoonLake Immunotherapeutics — Submission
- 2026-09-30: Nanobody (sonelokimab) - (VELA-2) — MoonLake Immunotherapeutics — Submission
- 2026-09-30: Anaphylm (dibutepinephrine) - (103) — Aquestive Therapeutics Inc. — Submission
- 2026-09-30: ESK-001 - (LUMUS) — Alumis Inc. — Topline Data
- 2026-09-30: REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM) — PLUS THERAPEUTICS Inc. — End of Phase Meeting
- 2026-09-30: UGN-103 - (UTOPIA) — UroGen Pharma Ltd. — Submission
- 2026-09-30: BDC-4182 — Bolt Biotherapeutics Inc. — Initial Data
- 2026-09-30: Azetukalner (XEN1101) - (X-TOLE2) — Xenon Pharmaceuticals Inc. — Submission
- 2026-09-30: Rademikibart - (Seabreeze STAT Asthma) — Connect Biopharma Holdings Limited — Topline Data
- 2026-09-30: Rusfertide - (REVIVE) — Protagonist Therapeutics Inc. — Regulatory Decision
- 2026-09-30: DT120 ODT (MM120) lysergide tartrate - (Panorama) — Definium Therapeutics Inc. — Topline Data
- 2026-09-30: MN-001 (Tipelukast) - (NATG-202) — MediciNova Inc. — Topline Data
- 2026-09-30: VK2735 - (VANQUISH-2) — Viking Therapeutics Inc. — Interim Data
- 2026-09-30: NXC-201 (HBI10101) - (NEXICART-2) — Immix Biopharma Inc. — Full Results
- 2026-09-30: Brepocitinib - (VALOR) — Pfizer Inc. — Regulatory Decision
- 2026-09-30: Oveporexton (TAK-861-2001) — Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) — Regulatory Decision
- 2026-09-30: AMT-130 — uniQure N.V. — Submission
- 2026-09-30: Halneuron - (HALT-CINP / HAL-CINP-203) — Dogwood Therapeutics Inc. — Topline Data
- 2026-09-30: Bezisterim (NE3107) - (ADDRESS-LC) — BioVie Inc. — Topline Data
- 2026-09-30: Deucrictibant (PHVS416) - (CHAPTER-3) — Pharvaris N.V. — Topline Data
- 2026-09-30: TX2100 — Tectonic Therapeutic Inc. — Topline Data
- 2026-09-30: AL001-BD01 - (Lithium in Brain) — Alzamend Neuro Inc. — Initial Data
- 2026-09-30: Mim8 - (FRONTIER5) — Novo Nordisk A/S — Regulatory Decision
- 2026-09-30: OPGx-BEST1 — Opus Genetics Inc. — Full Results
- 2026-09-30: Enhertu (trastuzumab deruxtecan) - (DESTINY-Breast05) — AstraZeneca PLC — Regulatory Decision
- 2026-09-30: VYD2311 - (DECLARATION) — Invivyd Inc. — Topline Data
- 2026-09-30: Foralumab - (INFORM-MS) — Tiziana Life Sciences Ltd — Topline Data
- 2026-09-30: SCY-247 — SCYNEXIS Inc. — Topline Data
- 2026-09-30: Nintedanib Dpi (Mnkd-201) - (INFLO-1) — MannKind Corporation — Interim Data
- 2026-09-30: TNX-103 (oral levosimendan) - (LEVEL) — Tenax Therapeutics Inc. — Topline Data
- 2026-09-30: COMP360 psilocybin - (COMP006) — COMPASS Pathways Plc — Submission
- 2026-09-30: DT120 ODT (MM120) (lysergide D-tartrate, LSD) - (Voyage) — Definium Therapeutics Inc. — Topline Data
- 2026-09-30: Avexitide (Exendin 9-39) - (LUCIDITY) — Amylyx Pharmaceuticals Inc. — Initial Data
- 2026-09-30: SPY001, SPY002, SPY003 - (SKYLINE) — Spyre Therapeutics Inc. — Interim Data
- 2026-09-30: CYWC628 — FibroBiologics Inc. — Initial Data
- 2026-09-30: Efgartigimod - (ALKIVIA) — argenx SE — Topline Data
- 2026-09-30: EVO756 — Evommune Inc. — Initial Data
- 2026-09-30: CNM-Au8 - (HEALEY ALS) — Clene Inc. — Submission
- 2026-09-30: Bezisterim (NE3107) - (SUNRISE-PD) — BioVie Inc. — Topline Data
- 2026-09-30: PMN310 - (PRECISE-AD) — ProMIS Neurosciences Inc. — Topline Data
- 2026-09-30: 4D-150 - (PRISM) — 4D Molecular Therapeutics Inc. — Conference Presentation
- 2026-09-30: SPY072 - (SKYWAY-RD, basket study) — Spyre Therapeutics Inc. — Topline Data
- 2026-09-30: VK2735 - (VENTURE) — Viking Therapeutics Inc. — Interim Data
- 2026-09-30: ABCL635 — AbCellera Biologics Inc. — Topline Data
- 2026-09-30: Tarcocimab tedromer (KSI-501) - (DAYBREAK) — Kodiak Sciences Inc — Topline Data
- 2026-09-30: VYD2311 - (LIBERTY) — Invivyd Inc. — Topline Data
- 2026-09-30: Pemvidutide - (RECLAIM) — Altimmune Inc. — Topline Data
FDA Events Calendar
September 2026
Sun
Mon
Tue
Wed
Thu
Fri
Sat
1
3
5
9
12
13
14
17
18
20
25
29
Clinical Read
Regulatory
Meetings & Presentations